Literature DB >> 12436496

European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

K Tatsch, S Asenbaum, P Bartenstein, A Catafau, C Halldin, L S Pilowsky, A Pupi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12436496

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

Review 2.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

3.  The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Authors:  Orazio Schillaci; Mariangela Pierantozzi; Luca Filippi; Carlo Manni; Livia Brusa; Roberta Danieli; Giorgio Bernardi; Giovanni Simonetti; Paolo Stanzione
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-08       Impact factor: 9.236

4.  Iterative reconstruction or filtered backprojection for semi-quantitative assessment of dopamine D₂ receptor SPECT studies?

Authors:  Walter Koch; Christine Suessmair; Klaus Tatsch; Gabriele Pöpperl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

5.  Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.

Authors:  Deniz Kahraman; Carsten Eggers; Harald Schicha; Lars Timmermann; Matthias Schmidt
Journal:  J Neurol       Date:  2011-07-13       Impact factor: 4.849

6.  Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom.

Authors:  Walter Koch; Perry E Radau; Wolfgang Münzing; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-25       Impact factor: 9.236

Review 7.  Imaging of the dopaminergic system in differential diagnosis of dementia.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

8.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

9.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

10.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.